Impact of Myocardial Ischemia and Revascularization by Percutaneous Coronary Intervention on Circulating Level of Soluble ST2

References

• Ahern RM, Lozano R, Naghavi M, Foreman K, Gakidou E, Murray CJ. Improving the public health utility of global cardiovascular mortality data: the rise of ischemic heart disease. Popul Health Metr. 2011;9(1):8. doi:10.1186/1478-7954-9-8
   PubMedGoogle Scholar
• Ciccone MM, Cortese F, Gesualdo M, et al. A novel cardiac bio-marker: ST2: a review. Molecules. 2013;18(12):15314–15328. doi:10.3390/molecules181215314
   PubMed Web of Science ®Google Scholar
• Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7(10):827–840. doi:10.1038/nrd2660
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–2966. doi:10.1161/01.cir.0000038705.69871.d9
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538–1549. doi:10.1172/JCI30634
   PubMed Web of Science ®Google Scholar
• Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2(6):684–691. doi:10.1161/CIRCHEARTFAILURE.109.873240
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239. doi:10.1016/j.jacc.2013.05.019
   PubMed Web of Science ®Google Scholar
• Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol. 2001;166(11):6633–6639. doi:10.4049/jimmunol.166.11.6633
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• Brown AM, Wu AHB, Clopton P, Robey JL, Hollander JE. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann Emerg Med. 2007;50(2):153–158.e1. doi:10.1016/j.annemergmed.2007.02.015
   PubMed Web of Science ®Google Scholar
• Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail. 2012;18(4):304–310. doi:10.1016/j.cardfail.2012.01.008
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Pascual-Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol. 2015;115(7 Suppl):70B–5B. doi:10.1016/j.amjcard.2015.01.044
   PubMed Web of Science ®Google Scholar
• Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J. 2013;165(6):995–999. doi:10.1016/j.ahj.2013.02.029
   PubMed Web of Science ®Google Scholar
• Alkhateeb A, Abd Elrady NS, Ali AMS, Hashim AKA. Impact of diabetes mellitus on acute and short term left ventricular longitudinal systolic strain recovery after percutaneous coronary intervention in ischemic hypertensive patients. SVU Int J Med Sci. 2023;6(2):152–159. doi:10.21608/svuijm.2023.202042.1556
   Google Scholar
• Gensini GG. Coronary Arteriography / by Goffredo G. Gensini Mount Kisco, N.Y: Futura Pub. Co; 1975.
   Google Scholar
• Golabchi A, Sadeghi M, Sanei H, et al. Can timi risk score predict angiographic involvement in patients with st-elevation myocardial infarction? ARYA Atheroscler. 2010;6(2):69–73.
   PubMedGoogle Scholar
• Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012;58(12):1673–1681. doi:10.1373/clinchem.2012.192153
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization [published correction appears in. Eur Heart J. 2019;40(37):3096. doi:10.1093/eurheartj/ehy394
   PubMed Web of Science ®Google Scholar
• Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 1990;119(6):1262–1267. doi:10.1016/s0002-8703(05)80173-5
   PubMed Web of Science ®Google Scholar
• Adams MR, Nakagomi A, Keech A, et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 1995;92(8):2127–2134. doi:10.1161/01.cir.92.8.2127
   PubMed Web of Science ®Google Scholar
• Zhang T, Xu C, Zhao R, Cao Z. Diagnostic Value of sST2 in Cardiovascular Diseases: a Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021;8:697837. doi:10.3389/fcvm.2021.697837
   PubMed Web of Science ®Google Scholar
• Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. Am J Cardiol. 2015;115(7 Suppl):48B–58B. doi:10.1016/j.amjcard.2015.01.041
   PubMed Web of Science ®Google Scholar
• Crnko S, Printezi MI, Jansen TPJ, et al. Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients. ESC Heart Fail. 2020;7(3):1224–1233. doi:10.1002/ehf2.12673
   PubMed Web of Science ®Google Scholar
• Eggers KM, Armstrong PW, Califf RM, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J. 2010;159(5):788–794. doi:10.1016/j.ahj.2010.02.022
   PubMed Web of Science ®Google Scholar
• Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109(18):2186–2190. doi:10.1161/01.CIR.0000127958.21003.5A
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2014;60(3):530–540. doi:10.1373/clinchem.2013.209858
   PubMed Web of Science ®Google Scholar
• Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–250. doi:10.1016/j.jacc.2009.08.047
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117(15):1936–1944. doi:10.1161/CIRCULATIONAHA.107.728022
   PubMed Web of Science ®Google Scholar